SCHEMBL26967289

SCHEMBL26967289

CC(C)(C)OC(=O)N1CCN(c2ncnc3c(F)c(Br)c(C#C[Si](C)(C)C)cc23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.46
KCNH2 Q12809 2/20 0.39
MAP4K4 O95819 1/20 0.38
GRIA1 P42261 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GALR2 O43603 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GPR119 Q8TDV5 4/20 0.37
CXCR2 P25025 1/20 0.36
KRAS P01116 2/20 0.35
TLR9 Q9NR96 1/20 0.35
EGFR P00533 1/20 0.35
HMOX2 P30519 1/20 0.35
CRYZ Q08257 1/20 0.35
VAT1 Q99536 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26967418 0.88 KIT (0.48) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL16647196 0.85 KIT (0.52) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL16636962 0.83 KIT (0.50) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL26967337 0.83 KIT (0.50) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL29611722 0.83 KIT (0.50) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL24918229 0.82 KIT (0.49) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL26967463 0.79 KIT (0.46) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL30902158 0.78 KIT (0.52) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL31029660 0.78 KIT (0.52) KITKCNH2MAP4K4GRIA1CNR1
SCHEMBL21415508 0.78 KIT (0.52) KITMAP4K4GRIA1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246954-A1 COMPOSITIONS AND METHODS FOR INHIBITING KRAS THERAS, INC. 2024-07-25 US disclosed
EP-4294799-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Theras Inc. (US) 2023-12-27 EP disclosed
CN-117157290-A Compositions and methods for inhibiting KRAS 瑟拉斯有限公司 2023-12-01 CN disclosed
WO-2022177917-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF RAS THERAS, INC. (US) 2022-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246954-A1 COMPOSITIONS AND METHODS FOR INHIBITING KRAS KRAS, NRAS, HRAS KIT 1978/4885KCNH2 4762/4885MAP4K4 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.